Polyphenols constitute a family of natural substances distributed widely in plant kingdom. These are produced as secondary metabolites by plants and so far 8000 representatives of this family have been identified. Recently, there is an increased interest in the polyphenols because of the evidence of their role in prevention of degenerative diseases such as neurodegenerative diseases, cancer, and cardiovascular diseases. Although a large number of drugs are available in the market for treatment of these diseases, however, the emphasis these days is on the exploitation of natural principles derived from plants. Most polyphenols show low in vivo bioavailability thus limiting their application for oral drug delivery. This low bioavailability could be associated with low aqueous solubility, first pass effect, metabolism in GIT, or irreversible binding to cellular DNA and proteins. Therefore, there is a need to devise strategies to improve oral bioavailability of polyphenols. Various approaches like nanosizing, self-microemulsifying drug delivery systems (SMEDDS), microencapsulation, complexation, and solid dispersion can be used to increase the bioavailability. This paper will highlight the various methods that have been employed till date for the solubility enhancement of various polyphenols so that a suitable drug delivery system can be formulated.

1. Introduction

Naturally occurring active moieties have been used in therapy since ages. Currently 80% of the world’s population uses plant derived principles either directly or indirectly [1]. Certain examples of plant derived products employed as therapeutic agents are tannins, alkaloids, polyphenols, polysaccharides, essential oils, various extracts, and exudates. Lately, much research has been envisaged on polyphenols due to two main reasons. Firstly, these possess high spectrum of biological activities including antioxidant, anti-inflammatory, antibacterial, and antiviral and secondly, they are present in abundance in diet [2]. Polyphenols are found in many components of the human food including peanuts, dark chocolate, green and black tea, and turmeric. Extensive research in the past years and collected data shed light on certain physiological properties of plant polyphenols. These can slow the progression of certain cancers, neurodegenerative diseases, and diabetes and can reduce the risks of cardiovascular disease, thus highlighting the importance of the use of plant polyphenols as potential chemopreventive and anticancer agents in humans [3]. Many medicinal plants constitute polyphenols as active substances that modulate the activity of a wide range of enzymes and cell receptors [4]. However, the concentrations of polyphenols which appear effective in vitro are often of an order of magnitude lower than that required to elicit response in vivo, thus indicating their low bioavailability [5]. The bioavailability of polyphenols following oral administration is governed by many factors such as gastric residence time, permeability, and/or solubility within the gut. Further, the conditions encountered in food processing and storage (temperature, oxygen, and light) or in the gastrointestinal tract (pH, enzymes, and presence of other nutrients) may also influence the stability of polyphenols. Poor aqueous solubility and low dissolution rates of polyphenols contribute to their insufficient bioavailability [6]. There are two parameters that are useful for identifying a poorly soluble drug, the aqueous solubility and the dose: solubility ratio. A drug is classified as poorly soluble if it has less than 100 μg/mL solubility. Dose: solubility ratio is defined as volume of gastrointestinal fluids necessary to dissolve the administered dose [7]. The majority of polyphenols...
belong to class II (low solubility and high permeability) and class IV (low solubility and low permeability) BCS classes thus limiting activity and potential health benefits of polyphenols. The bioavailability of class II and class IV substances may be enhanced by increasing the solubility and dissolution rate of the drug in the gastrointestinal fluid. Table 1 depicts solubility and pharmacokinetic properties of some commonly used polyphenols [8–15]. The solubility of polyphenols can be enhanced by various techniques. Techniques used for improving solubility include inclusion complexes, micronization, solid dispersion, nanosuspension, solid lipid nanoparticles, nanostructured lipid carrier, liposomes, self-emulsifying drug delivery systems (SEDDS), and gel based systems. Table 2 depicts some of commonly employed methods for increasing the solubility [16–23]. The present review discusses the various methods used till date to improve the bioavailability of polyphenols by enhancing their solubility.

2. Polyphenols: Types and Method for Solubility Enhancement

Several higher plants and some edible plants comprehend thousand molecules having a polyphenol structure (i.e., several hydroxyl groups on aromatic rings). These molecules are released as defense against ultraviolet radiation or aggression by pathogens and are a kind of secondary metabolites. The polyphenols are classified on the basis of the number of phenol rings that they contain and of the structural elements that bind these rings to one another. These are hence categorized into phenolic acids, flavonoids, stilbenes, and lignans. Figure 1 depicts the chemical structure of polyphenols.
| Method                                      | Procedure                                                                 | Advantages                                                                 | Disadvantages                                                                 | Example                          | Reference        |
|---------------------------------------------|---------------------------------------------------------------------------|---------------------------------------------------------------------------|-------------------------------------------------------------------------------|----------------------------------|------------------|
| Nanoparticles                               |                                                                           |                                                                           |                                                                               |                                  |                  |
| Evaporative precipitation into aqueous solution | Spraying of drug solution through an atomizer into an aqueous solution containing stabilizer at high temperature. | High dissolution rate, high surface area, enhanced wettability.             | Require stabilizers, lack of controlled release, not suitable for thermolabile drugs | Nanosuspension of quercetin      | [45]             |
| High pressure homogenization                 | Precipitation of drug by addition of antisolvent in the drug solution leading to formation of unstable form of drug which is stabilized by means of single/repeated application of high energy followed by thermal relaxation (annealing). | Reduced particle size, enhanced dissolution, no crystal growth             | Long processing time, introduction of impurities, high energy requirements, chemical degradation | Nanosuspension of quercetin      | [45]             |
| Antisolvent method                          |                                                                           |                                                                           |                                                                               |                                  |                  |
| Antisolvent precipitation using a syringe pump | Addition of antisolvent to a solution of drug and solvent at a particular flow rate under constant stirring leading to precipitation of drug which is then filtered to collect nanoparticles. | Reduced particle size, high dissolution rate, high surface area, reduced crystallinity, faster onset of action | Contamination due to filtration | Nanoparticles of hesperetin | [65]             |
| Evaporative precipitation of nanosuspension  | Mixing of a water miscible solvent containing drug with an antisolvent followed by evaporation of solvents. | Decreased particle size, enhanced surface area, improved dissolution       | Particle growth due to remaining organic solvent in suspension                | Curcumin nanoparticles           | [92]             |
| Supercritical antisolvent method            | Precipitation of drug from drug solution by mixing it with a compressed fluid at its supercritical conditions. Diffusion of solvent into antisolvent phase leads to drug precipitation due to low solubility of drug in antisolvent. | High product purity, controlled crystal polymorphism, possible processing of thermolable molecules, single step process | Toxicity and flammability of solvents, poor control of particle morphology, incomplete removal of residual solvent | Apigenin nanocrystals           | [55]             |
| Solid dispersion                            | Formation of eutectic mixtures of drugs with hydrophilic carriers by melting their physical mixtures | Particle size reduction, improved wettability, enhanced dissolution, higher porosity | Decrease in dissolution on aging, crystal growth upon moisture absorption, demixing, phase separation | Solid dispersion of ellagic acid | [19–21, 37]    |
| Self-microemulsifying drug delivery systems | Gentle mixing of drug, oil, surfactant, and cosurfactant in aqueous media leading to formation of o/w microemulsion of drug droplets with mean droplet size <100 nm. | Higher bioavailability, improved absorption, oral administration using gelatin capsules | Surfactant toxicity, tedious manufacturing method, interaction with capsule shell | Curcumin                        | [22, 23, 96]    |
2.1 Phenolic Acids. They are plant derived phenolic compounds which are produced via shikimic acid through phenylpropanoid pathway and have a unique chemical structure of $C_6-C_3$. Some phenolic acids are also of microbial origin containing $C_6-C_1$ linkage. These are further classified into two categories: derivatives of cinnamic acid (hydroxycinnamic acids) and derivatives of benzoic acid (hydroxybenzoic acids).

2.1.1 The Hydroxycinnamic Acids (Figure 1(b)). They are more common than the hydroxybenzoic acids and consist mainly of $p$-coumaric acid, caffeic acid, ferulic acid, and sinapic acid. These acids are found in glycosylated forms as derivatives of shikimic acid, quinic acid, and tartaric acid. Caffeic acid combines with quinic acid to form chlorogenic acid (Figure 1(c)). It is found in high concentrations in coffee: a single cup may contain 70–350 mg chlorogenic acid [24]. Caffeic acid is the most abundant phenolic acid in coffee and represents between 75 and 100% of the total hydroxycinnamic acid content of most of the fruit. All parts of the fruit contain hydroxycinnamic acid but the highest concentrations are seen in the outer parts of ripe fruit. Cereal grains are dietary source of ferulic acid. Wheat grains may contain 0.8–2 g/kg dry weight of ferulic acid, which represents up to 90% of total polyphenols [25, 26]. Since, hydroxybenzoic acids possess sufficient aqueous solubility their absorption is not dissolution limited.

2.1.2 Hydroxybenzoic Acids (Figure 1(a)). Salient examples of hydroxybenzoic acids are gallic acid, protocatechuic acid, ellagic acid (EA), and vanillic acid. Edible plants for example, red fruits, black radish, onions, and green tea are rich in hydroxybenzoic acid content [27]. Tea is an important source of gallic acid and tea leaves may contain up to 4.5 g/kg fresh wt of leaves [24, 28]. Dietary sources of EA include walnuts, pomegranates, and berries [29]. EA possesses several health benefits against many diseases such as breast cancer [30], prostate cancer [31], lung cancer [32], colon cancer [33], cardiovascular disease [34], and neurodegenerative diseases [35]. EA was found to possess maximum solubility of 9.3 $\mu$g/mL [36]. This low solubility was attributed to high crystallinity of EA due to its planar and symmetrical structure and extensive hydrogen-bonding resulting in low bioavailability of EA. Solid dispersions of EA have been employed to enhance the solubility of EA. Li et al. [37] formulated solid dispersions of EA by three different methods. Table 3 depicted the methods and compositions of these investigational formulations. Fourier transform infrared spectroscopy (FTIR) studies confirmed the presence of H-bonding between EA and polymers. Scanning electron microscope (SEM) studies indicated that EA was present in amorphous form in the solid dispersions. The in vitro dissolution studies revealed that the nature of polymer directly influences the solubility of EA. The polymer with more hydrophilic character resulted in higher swelling and faster release of EA. Thus, the release profile of EA from EA/PVP matrix was 92% (1 h) followed by EA/HPMCAS (35%, 0.5 h), EA/CMCAB (18%, 1 h), and EA/CAAdP (15–17%, 1 h). Incorporation of CAAdP in EA/PVP solid dispersion led to a decrease in release of EA (62%, 0.5 h). EA has been reported to deteriorate in the solution form due to crystallization and chemical degradation. The amount of EA remaining after 24 h in solution is only 18% and 80% due to crystallization and chemical degradation, respectively. However, the solid dispersions were found to significantly enhance the stability of EA against crystallization and chemical degradation. Further, it was found that HPMCAS amorphous solid dispersion provided maximum stability to EA [37].

2.2 Flavonoids. These are benzo-$\gamma$-pyrone derivatives of phenolic and pyran rings [38]. On the basis of substitutions on three rings, flavonoids are classified as flavonols, flavones, isoflavones, flavanones, and anthocyanidins which are biotransformed in body by methylation, sulfation, and glucuronidation of hydroxyl groups. Flavonoids predominantly exist as 3-O-glycosides and polymers [39]. Chemical structure of flavonoids is illustrated in Figure 2.

### Table 3: Different methods for solid dispersions of ellagic acid [37].

| Method                        | Composition                                                                 | Procedure                                                                                           |
|-------------------------------|-----------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------|
| Spray-dried solid dispersion  | Acetone : ethanol (1:4 v/v) solution, ellagic acid, polyvinylpyrrolidone (PVP), carboxymethyl cellulose acetate butyrate (CMCAB), hydroxypropyl methyl cellulose acetate succinate (HPMCAS) | Acetone : ethanol solution was used to dissolve mixtures of EA/polymer followed by spray drying of the resultant dispersion under operating conditions of 90°C inlet temperature, 57–60°C outlet temperature, 9 mL/min feed rate, and 350 L/h nitrogen flow. |
| Coprecipitated solid dispersion| Ellagic acid, tetrahydrofuran (THF), cellulose acetate adipate propionate (CAAdP) | A mixture of EA/CAAdP was dissolved in THF followed by dropwise addition of the solution in deionized water with stirring. |
| Solid dispersion by rotary evaporation | Ellagic acid (20 mg), PVP (90 mg), CAAdP (90 mg), acetonitrile : ethanol (1:1 v/v) solution (40 mL) | EA, PVP, and CAAdP were dissolved in acetonitrile : ethanol solution followed by concentrating the solution with rotary evaporation |
but other sugars like galactose, arabinose, and xylose may also be involved. Each fruit contains around 5–10 different flavonol glycosides [40]. The biosynthesis of flavonols is stimulated by light, so these tend to accumulate in the outer and aerial tissues. Depending on exposure to sunlight, differences in concentration exist between fruits on the same tree and even between different sides of a single fruit [41].

Quercetin. It is a naturally occurring polyphenol which belongs to a group of plant pigments known as flavonoids, responsible for the colour of vegetables, fruits, and flowers [42]. Quercetin is a flavonol whose chemical structure is derived from flavone. Chemically quercetin is known as 3,3',4',5,7-pentahydroxyflavone. Quercetin exhibits various properties such as anti-inflammatory, antioxidant, antihistamine, and antiarthritic [42]. The primary dietary sources of quercetin are citrus fruits, apple, onions, parsley, sage, tea, and red wine [43]. However, despite having all these beneficial activities, poor water solubility (0.3 µg/mL) restricts its use thus highlighting the importance of increasing the solubility of quercetin [44]. Gao et al. [45] reported the formation of nanosuspension of quercetin by two techniques. The first technique is comprised of evaporative precipitation of quercetin into aqueous solution (EPAS). The organic solution of quercetin in ethanol was poured slowly into an aqueous solution containing Pluronic F68 (0.75% w/v) and lecithin (0.25% w/v). A piston gap high pressure homogenizer was used to circulate the suspension for two cycles at the pressure of 200 bar and five cycles at 500 bar followed by 20 more cycles at 1500 bar resulting in HPH suspension. The mean particle size, polydispersity index (PI), and solubility profile of quercetin nanosuspension produced by EPAS method and HPH method were found to be 282.6 ± 50.3 nm, 0.23 ± 0.08, 422.4 µg/mL and 213.6 ± 29.3 nm, 0.21 ± 0.10, 278.6 µg/mL, respectively. X-ray powder diffraction (XRPD) measurements revealed a crystalline to amorphous phase transition in EPAS process, which was not observed in HPH. This formed the basis for higher increase in solubility of quercetin in case of EPAS [46].

A solid dispersion of quercetin employing CMCA, HPMCAS, and CAAdP as polymers has been reported by Li et al. [47]. Quercetin and polymer mixtures were prepared in different ratios of 1:9, 1:3, 1:1, 3:1, and 9:1. Acetone : ethanol (1:4) solution was used to dissolve the above mixtures to form 2% w/v solution. The solutions were spray-dried using inlet temperature 90°C, outlet temperature 57–60°C, feed rate 9 mL/min, and nitrogen flow rate 350 L/h. XRPD studies of the formulations revealed that while quercetin/CMCAB had identical crystallinity, quercetin/CAMLP and CAMC displayed amorphous character and quercetin/HPMCAS displayed partial crystalline character with respect to crude quercetin. FTIR spectra of the formulations showed broadening of peak at 3300–3500 cm⁻¹ which was attributed to the presence of intermolecular H-bonding between quercetin and matrix polymer, further decreasing crystalline structure of quercetin. A comparison of release profiles of quercetin solid dispersion with quercetin powder indicated that the solid dispersions quercetin/HPMCA, quercetin/CMCAB,

![Figure 2: Classification and chemical structure of flavonoids.](image-url)
and quercetin/CAAdp showed 14% release after 0.5 h whereas the dissolution of quercetin powder was found to be 0.7% even after 1 h.

Inclusion complexes of quercetin have also been reported for increasing solubility of quercetin [48]. An inclusion complex of quercetin was made with β-cyclodextrin (βCD), hydroxypropyl-β-cyclodextrin (HP-βCD), and sulfobutyl ether-β-cyclodextrin (SBE-βCD) (ranging from 0 to 0.01 M). The 1:1 complex between quercetin and cyclodextrins led to increased solubility of quercetin in the order of βCD < HP-βCD < SBE-βCD [49].

2.2.2. Flavones. They are much more prevalent than flavonols in fruit and vegetables. Flavones primarily contain glycosides of luteolin and apigenin (Figure 2(f2)). The important savory sources of flavones are parsley and celery. C-glycosides of flavones are encompassed in cereals such as millet and wheat [50, 51].

**Apigenin (AP).** It is a naturally occurring flavone chemically known as 4′,5,7-trihydroxyflavone. The most prevalent natural sources of AP are parsley, celery, and chamomile tea [52]. AP belongs to BCS class II with poor aqueous solubility and high permeability in intestine. AP was found to possess maximum solubility 2.16 μg/mL at pH 7.5 resulting in low dissolution and poor bioavailability [53]. Various formulation strategies have been devised to overcome this problem. High shear mixing for preparation of AP smart crystals has been reported by Al Shaal et al. [54] for solubility enhancement of AP.

Smart crystal technology comprehends combination of different processes, pretreatment of poorly soluble drug followed by high pressure homogenization. A macrosuspension of AP powder and surfactant solution (Plantacare 2000 UP, 1% w/w) was formed by high shear mixing (Ultra-Turrax T25, 10,000 rpm). This was followed by seven passages through bead milling (Buhler PML-2). The formed nanosuspension was then subjected to high pressure homogenization (Avestin C50, 300 bar/cycle). The pretreatment step was included to accelerate nanocrystals production by reducing homogenization cycles and to decrease particle size. Milling medium used was zirkonia and yttria was employed as a stabilizer. The mean particle size of AP was found to be 439 ± 20 nm with a low PI of 0.283 ± 0.040. Light microscopy studies also presented evidence supporting the use of surfactant by showing an image with uniform crystal distribution with no signs of large crystals and aggregates in the presence of surfactant. A zeta potential of −38 mV was reported which indicated a well charged surface and related stability. AP coarse powder and nanoparticles showed identical X-ray diffraction (XRD) pattern indicating no decrease in crystallinity. DPPH (2,2-diphenyl-1-picrylhydrazyl) radical scavenging test showed a 2-fold increase in antioxidant activity of AP nanoparticles as compared to AP macrosuspension.

Another method for improvement in solubility of AP has been reported by Zhang et al. [55]. The study incorporated preparation of AP nanocrystals via supercritical antisolvent method (SAS). Figure 3 depicts a schematic representation of preparation of nanoparticles. Photon correlation spectroscopy (PCS) studies revealed the particle size to be 562.5 ± 56 nm with a PI value of 0.92 ± 0.21. Reduced degree of crystallinity was represented in XRPD diagram. Differential scanning calorimetry (DSC) curves of AP coarse powder and AP nanocrystals were studied and compared. A decrease in melting point of AP was observed with nanoparticles which could be attributed to particle size reduction to nanometer range. FTIR patterns were identical for both coarse powder and nanoparticles thus indicating the chemical stability of AP during SAS process. AP nanocrystals exhibited more rapid dissolution rate with much higher cumulative amount of dissolved AP than AP coarse powder. The higher dissolution of AP nanocrystals could be due to the enhanced saturated

---

**Figure 3: Steps involved in SAS method for preparation of nanoparticles [55].**

- **Liquefaction of CO₂ using low temperature thermostat bath**
  - **High pressure pump**
  - **Compression of liquefied CO₂**
  - **Depressurization to atmospheric pressure**
  - **Washing out residual DMSO**
  - **Flow of supercritical CO₂**
  - **Collection of nanoparticles**
  - **Delivery of CO₂ to crystallization vessel through metal filter screen**
  - **DMSO recovered in solvent recovery kettle**
  - **CO₂ exhausted out through rotameter**
  - **Preheater**
  - **Preheating of CO₂**
  - **Apigenin in DMSO solution**
  - **pumped through high pressure infusion pump**
  - **Flow of supercritical CO₂ into vessel**
  - **Depressurization to atmospheric pressure**
  - **Washing out residual DMSO**
  - **Collection of nanoparticles**

---

*a* Apigenin dissolved in DMSO (20 mg/mL)

*b* Infusion rate = 0.5 mL/min

*c* Supercritical conditions of CO₂ = 14.5 MPa, 35°C
solubility resulting from a significant decrease of particle size [56]. In vivo studies showed 3.6 and 3.4 fold enhancement in C_{max} and AUC of AP, respectively, after oral administration of AP nanocrystals. The absolute bioavailability of AP coarse powder was found to be 2.0% whereas nanoparticles exhibited 6.9% absolute bioavailability. Thus improved solubility, dissolution rate, and bioavailability depict the usefulness of these methods for delivery of such BCS class second compounds.

2.2.3. Flavanones. They are natural compounds of restricted occurrence and are sometimes termed as minor flavonoids. The cardinal aglycones are naringenin, hesperetin, and eriodictyol (Figure 2(f4)). Glycosylation of flavanones is generally attained by a disaccharide at position 7, which is either a neohesperidose, that imparts a bitter taste (such as to naringin in grapefruit), or a rutinose, which is flavorless. Citrus fruits contain considerable amount of flavanones. Tomatoes and certain aromatic plants such as mint also constitute flavanones. Hesperidin and narinrutin are present in orange juice at a concentration of 200–600 mg/L and 15–85 mg/L, respectively. A single glass of orange juice may contain between 40 and 140 mg of flavanone glycosides [57]. However, very high flavanone content is found to be present in the solid parts of orange fruit, particularly the albedo (the white spongy portion), and the membranes separating the segments. Thus an orange fruit may comprise up to 5 times as much as a glass of orange juice.

(1) Hesperetin. It is a naturally occurring flavonoid chemically known as 3',5,7-trihydroxy-4-methoxylavonane. Hesperetin is found almost exclusively in citrus fruits [58]. Studies revealed that hesperetin can avert colon [59], urinary bladder [60], and chemically induced mammary carcinogenesis [61]. Other biological activities of hesperitin include antioxidant [62] and anti-inflammatory [63]. Aqueous solubility of hesperetin was found to be 1.4 μg/mL [64]. Nanoparticles of hesperetin by two different methods namely APSP and EPN have been have been reported to enhance the solubility and dissolution rate [65].

APSP. The solvent and antisolvent used in this method were ethanol and deionized water, respectively. The method comprised of dissolution of hesperetin in solvent followed by injection of drug solution into an antisolvent with the help of syringe. The solution was constantly stirred using magnetic stirrer (200–1000 rpm) and the flow rate was varied from 2 to 10 mL/min.

EPN. Nanoparticles in this method were formed by quick addition of drug solution containing hesperetin and ethanol into antisolvent. Hexane was used as antisolvent. Vacuum drying was carried out for quick evaporation of solvent leading to formation of nanosuspension.

Figures 4(a) and 4(b) depict the effect of various parameters on particle size and solubility of hesperetin by APSP and EPN methods. The formulation containing 5 mg/mL drug concentration, 10 mL/min flow rate, stirring speed of 1000 rpm, and solvent:antisolvent ratio of 1:20 depicted highest solubility (9.88 μg/mL). This was attributed to a decrease in particle size from 34 μm to 0.75 μm (revealed by SEM). In case of EPN highest solubility (11.17 μg/mL) was seen in formulation containing 5 μg/mL drug concentration and 1: 20 solvent : antisolvent ratio. The DSC studies revealed that the melting point of nanoparticles prepared by both methods was identical to crude hesperetin but enthalpy of fusion was reduced due to reduction in crystallinity of nanoparticles of hesperetin.

(2) Naringenin (NRG). It is a kind of flavanone (4',5,7-trihydroxyxylavonane), found extremely in tomatoes [66], cherries [67], grape fruit, and citrus fruits [58]. In addition to antioxidant property [68], NRG also possess anti-inflammatory [69], antitumour [70], and hepatoprotective effects [71]. However, clinical applicability of NRG is limited by its low solubility and bioavailability. NRG possesses low aqueous solubility (45 μg/mL) [72], therefore measures were taken to investigate methods for enhancing solubility of NRG. Transglycosylation of hesperetin leads to an increase in solubility of hesperetin [73]. This formed the basis for preparing spray-dried particles of NRG with α-Glucosyl hesperdin (Hsp-G) in order to enhance its solubility [72]. Different loading ratios of NRG/Hsp-G (1:1 to 1:20 w/w) were dissolved in ethanol: water (8:2 v/v) solution. The resultant suspension was then subjected to spray drying at the rate of 10 mL/min employing a spray nozzle of diameter 406 μm and pressure of 0.13 MPa. The inlet and outlet temperatures of drying chamber were 120°C and 70°C, respectively. SEM images of NRG/Hsp-G samples showed spherical shaped aggregates with average particle size of 3-4 μm. The resultant spray-dried particles of NRG showed 60-fold improvement in solubility when loading ratio of NRG/Hsp-G was 1:20.

2.2.4. Isoflavones. They have structural similarities to estrogens as they have hydroxyl groups in positions 7 and 4' in a configuration analogous to that of the hydroxyls in the estradiol molecule (Figure 2(f3)). Although isoflavones are not steroids, they have potential estrogenic activity. This illustrates their ability to bind to estrogen receptors. They possess pseudohormonal properties and are consequently classified as phytoestrogens [2]. Leguminous plants are the exclusive source of isoflavones. The main source of isoflavones in the human diet is soya and its processed products. Isoflavones principally contain 3 compounds: genistein, daidzein, and glycitein (concentration ratio of 1:1:0.2). Factors such as geographic zone, growing conditions, and processing of soya and its manufactured products greatly affect their isoflavone content. Isoflavone content of soybeans is 580–3800 mg/kg and of soymilk is 30–175 mg/L [74,75].

Genistein. It is a naturally occurring plant flavonoid. Soy products are the richest sources of genistein [76]. Chemical structure of genistein (4',5,7-trihydroxyxylavonane) contains an isoflavone backbone. Genistein has beneficial effects in areas of cancer [77], cardiovascular diseases [78], and postmenopausal symptoms [79]. Aqueous solubility of genistein is very poor, approximately 0.81 μg/mL [80], which leads to
low bioavailability of the drug. A solid dispersion of genistein in Pluronic F127 polymeric micelles has been reported for solubility enhancement by Kwon et al. [80]. An ethanolic solution of Pluronic F127 was used to dissolve genistein by constant stirring at 37°C for 30 min. The solution when evaporated led to formation of clear gel-like matrix. Addition of water and constant stirring resulted in formation of polymeric micelles containing genistein. The resulting solution was filtered employing 0.45 μm pore size membrane filter to remove any undissolved genistein followed by lyophilization at −80°C. Average particle size of genistein loaded polymeric micelles was found to be 27.76 ± 0.46 nm with PI of 0.26. In vitro drug release showed genistein release 48–58% in pH 1.2 medium and 44–82% in pH 6.8 medium which was attributed to higher solubilizing ability of polymeric micelles. The in vivo pharmacokinetic characterization showed an increase in $C_{\text{max}}$ from 1.22 to 5.68 μg/mL and decrease in $t_{\text{max}}$ from 0.55 to 0.20 h. The polymeric micelles also demonstrated enhanced bioavailability thus confirming enhanced genistein solubility and release in gastrointestinal tract.

2.3. Stilbenes. Stilbenes encompass a group of biologically active compounds; however, human diet comprises only few of these (Figure 1(e)). Examples may include trans-resveratrol and trans-piceid (its natural glycoside).

2.3.1. Resveratrol. It belongs to a class of naturally occurring polyphenols known as stilbenes. It is mainly present in the form of trans-resveratrol (3,5,4’-trihydroxystilbene) in human diet. The dietary sources of resveratrol include peanut butter, dark chocolate, blueberries, and red wine. About 2.3 mg/L of trans-resveratrol is present in red wine [81]. Resveratrol exhibits antiangiogenesis [82], cardioprotective [83], anticarcinogenic, and anti-inflammatory activities [84]. Aqueous solubility of resveratrol was found to be 30 μg/mL, thereby, limiting pharmaceutical potential of resveratrol [85]. Zhang et al. [86] reported a method for enhancing solubility of resveratrol by formulating nanoparticles of resveratrol using antisolvent precipitation method. The ethanolic solution of resveratrol (solvent) was poured with vigorous stirring (9000 rpm) into aqueous solution of polymer (antisolvent) resulting into precipitation of resveratrol after 30 s. Four different polymers that is, HPMC, PVP, PEG 400, and P188 were employed. The solvent:antisolvent ratio was kept constant at 1:20. Process parameters employed for spray drying were 105°C inlet temperature, 50–60°C outlet temperature,
1 mL/min spray flow rate, and 0.65 MPa atomization air pressure. The particle size obtained with HPMC, PVP, PEG 400, and PI88 was found to be 161 \pm 3, 116 \pm 78, 2168 \pm 26, and 1644 \pm 47 nm, respectively. Dissolution studies represented complete dissolution of resveratrol nanodisper-
sion in less than 45 min, whereas raw resveratrol did not
dissolve completely even after 120 min indicating increased
water solubility of resveratrol by using polymers.

2.4. Miscellaneous

2.4.1. Curcumin. It is a naturally occurring polyphenol which
is extracted from the plants of *Curcuma longa*. *Curcuma longa* (turmeric) has been used to treat ailments since a long
time ago. It is also employed as a spice in Indian cuisine.
Curcumin exhibits a variety of pharmacological actions such as antitumor [87], anti-HIV [88], antioxidant, and anti-
inflammatory [89]. However, the goodness of curcumin has not been able to reach up to its potential yet. The
maximum solubility of curcumin in plain aqueous buffer
pH 5.0 has been reported to be 11 ng/mL [90] and the oral
dose of curcumin for treating advanced colorectal cancer was
found to be 3.6 g/day [91]. Therefore, there is need to devise
strategies to increase solubility of curcumin. Nanoparticles
of curcumin employing antisolvent precipitation method
have been reported by Kakran et al. [92]. The antisolvent
precipitation involved two methods, namely, antisolvent pre-
cipitation using a syringe pump (APSP) and evaporative pre-
cipitation of nanosuspension (EPN). In first method ethanol
was used as solvent and deionized water as antisolvent. In
EPN method solvent was same but antisolvent employed
was hexane. Figure 5 depicts a schematic representation of
techniques employed for formulation of nanoparticles. The
effect of process variables such as stirring speed, flow rate,
solvent:antisolvent (S:AS) ratio, and drug concentration
was studied on particle size and solubility.

An increase in the stirring speed from 200 to 1000 rpm
in APSP leads to a decrease in particle size from 550 to
500 nm. An increase in stirring speed led to intensification
of micromixing between multiphases resulting in decrease in
particle size. Similar results were observed with a variation
in flow rate of curcumin solution. An increase in the flow
rate from 2 to 10 mL/min led to decrease in length of
curcumin particles from 2560 to 1860 nm since an increase
in flow rate resulted in rapid mixing. Further, an inverse
relationship was reported between amount of antisolvent
in SAS ratios and particle size. With an increase in S:AS
ratio 1:20 from 1:10, a decrease in length and diameter of
curcumin particles from 1860 and 930 nm to 390 and 340 nm,
respectively, was reported. The drug concentration exhibited




\[ \text{Curcumin was dissolved in ethanol} \]

\[ 20 \text{mL of above solution was filled in syringe} \]

\[ \text{Magnetic stirring} \ (200–1000) \text{ rpm} \]

\[ \text{Flow rate} \ (2–10 \text{mL/min}) \]

\[ \text{Solution was injected into deionized} \]

\[ \text{water} \]

\[ \text{Evaporation of ethanol and hexane} \]

\[ \text{Vacuum drying of nanoparticles} \]

\[ \text{Vacuum applied using rotary} \]

\[ \text{evaporator} \]

\[ \text{Figure 5: APSP and EPN techniques for nanoparticle formulation of curcumin [92].} \]

\[ ^a\text{Conc. of curcumin in ethanol—5–15 mg/mL.} \]

\[ ^b\text{Solvent to antisolvent ratio—1:10–1:20 (v/v).} \]
a direct relationship with particle size as greater supersaturation followed by faster nucleation rate and smaller particles was observed with an increase in drug concentration. The particle length increased from 930 to 965 nm with a change in drug concentration from 5 to 15 mg/mL. Further, DSC studies revealed a decrease in curcumin crystallinity owing to decrease in melting enthalpy of nanoparticles although melting point was identical to original curcumin. The solubility studies indicated that solubility of curcumin (0.58 ± 0.03 μg/mL) was increased by APSP and EPN methods to 7.48 ± 0.11 μg/mL and 8.23 ± 0.07 μg/mL, respectively, which was ascribed to a reduced particle size [93] and decreased crystallinity [46].

Figure 6 shows the schematic representation of preparation of three types of solid dispersions. Diffraction pattern of CSD-curcumin was identical with crystalline curcumin indicating high crystallinity of curcumin whereas ASD-curcumin was found to be amorphous. Release rates of amorphous solid dispersion, nanocrystal solid dispersion, and nanoemulsion formulation were found to be 95% (180 min), 80% (180 min), and 93% (60 min), respectively, thus, indicating enhanced solubility of curcumin with solid dispersions.

Self-Microemulsifying Drug Delivery Systems of Curcumin (SMEDDS). Use of SMEDDS as one of the approaches to enhance solubility, dissolution, and oral absorption of poorly water soluble drugs has gained interest recently [95]. Cui et al. [96] employed SMEDDS for enhancing solubility of curcumin. Curcumin loaded SMEDDS were formulated employing oil (ethyl oleate), surfactant (the mixtures of emulsifier OP : cremophor EL=40:1 w/w), and cosurfactant (PEG 400). Different concentrations of the three components were used and evaluated for particle size and solubility. The optimal concentration of oil, surfactant, and cosurfactant was

---

**Figure 6:** Formulation of curcumin solid dispersions [94].
found to be 12.5%, 57.5%, and 30%, respectively. According to transmission electron microscopy (TEM) images, the mean particle size of formulation after dilution with water was found to be 21 nm and the solubility of curcumin was enhanced to 21 mg/g. A rapid dissolution (85% in 10 min) was observed with SMEDDS whereas crude curcumin showed negligible release even after 60 min in both pH 1.2 and 6.8 buffer solutions. In vivo oral absorption of curcumin loaded SMEDDS depicted 3.8-time increase in absorption percentage of SMEDDS.

3. Conclusion

Increase in solubility of a therapeutic agent can enhance the bioavailability of that compound. Polyphenols are naturally occurring active principles with wide variety of physiological and biological activities. However, their therapeutic potential has not been exposed widely because of their low solubilities. This review discusses the various techniques employed so far for solubility enhancement of polyphenols. The different strategies for example, antisolvent precipitation, evaporative precipitation, high pressure homogenization, or SMEDDS resulted in approximately 15–20-fold enhancement in solubility and 3–5-fold enhancement in bioavailability for some polyphenols, thus suggesting that application potential of polyphenols can be enhanced by increasing their solubility.

Abbreviations

| Abbreviation | Definition |
|--------------|------------|
| AP | Apigenin |
| APSP | Antisolvent precipitation using a syringe pump |
| ASD | Amorphous solid dispersion |
| β-CD | β-Cyclodextrin |
| BCS | Biopharmaceutics classification system |
| CAAdP | Cellulose acetate adipate propionate |
| CSD | Nanocrystal solid dispersion |
| CMCAB | Carboxymethyl cellulose acetate butyrate |
| DPPH | 2,2-Diphenyl-1-picrylhydrazyl |
| EA | Ellagic acid |
| EPAS | Evaporative precipitation of nanosuspension |
| EPN | Evaporative precipitation of nanosuspension |
| HP-β-CD | Hydroxypropyl-β-cyclodextrin |
| HPH | High pressure homogenization |
| HPMC | Hydroxypropyl methyl cellulose |
| HPMCAS | Hydroxypropyl methyl cellulose acetate succinate |
| NRG | Naringenin |
| NE | Nanoemulsion |
| PEG | Polyethylene glycol |
| PVP | Polyvinylpyrrolidone |
| SAS | Supercritical antisolvent method |
| SBE-β-CD | Sulfobutyl ether-β-cyclodextrin |
| THF | Tetrahydrofuran |

Conflict of Interests

The authors declare that there is no conflict of interests regarding the publication of this paper.

References

[1] V. Atul Bhattaram, U. Graefe, C. Kohlert, M. Veit, and H. Derendorf, “Pharmacokinetics and bioavailability of herbal medicinal products,” Phytomedicine, vol. 9, no. 3, pp. 1-33, 2002.
[2] C. Manach, A. Scalbert, C. Morand, C. Rémy, and L. Jiménez, “Polyphenols: food sources and bioavailability,” The American Journal of Clinical Nutrition, vol. 79, no. 5, pp. 727–747, 2004.
[3] A. Scalbert and G. Williamson, “Dietary intake and bioavailability of polyphenols,” Journal of Nutrition, vol. 130, no. 8, pp. 2073S–2085S, 2000.
[4] E. Middleton Jr., C. Kandaswami, and T. C. Theoharides, “The effects of plant flavonoids on mammalian cells: implications for inflammation, heart disease, and cancer,” Pharmacological Reviews, vol. 52, no. 4, pp. 673–751, 2000.
[5] A. Scalbert, C. Manach, C. Morand, C. Rémy, and L. Jiménez, “Dietary polyphenols and the prevention of diseases,” Critical Reviews in Food Science and Nutrition, vol. 45, no. 4, pp. 287–306, 2005.
[6] G. L. Amidon, H. Lennernas, V. P. Shah, and J. R. Crison, “A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability,” Pharmaceutical Research, vol. 12, no. 3, pp. 413–420, 1995.
[7] C. M. O’Driscoll and B. T. Griffin, “Biopharmaceutical challenges associated with drugs with low aqueous solubility: The potential impact of lipid-based formulations,” Advanced Drug Delivery Reviews, vol. 60, no. 6, pp. 617–624, 2008.
[8] G. D. Stoner, C. Sardo, G. Apseloff et al., “Pharmacokinetics of anthocyanins and ellagic acid in healthy volunteers fed freeze-dried black raspberries daily for 7 days,” Journal of Clinical Pharmacology, vol. 45, no. 10, pp. 1153–1164, 2005.
[9] C. H. Cottart, V. Nivet-Antoine, C. Laguillier-Morizot, and J. L. Beaudeau, “Resveratrol bioavailability and toxicity in humans,” Molecular Nutrition and Food Research, vol. 54, no. 1, pp. 7–16, 2010.
[10] P. C. H. Hollman, J. M. P. van Trijp, M. N. C. P. Buysman et al., “Relative bioavailability of the antioxidant flavonoid quercetin from various foods in man,” FEBS Letters, vol. 418, no. 1-2, pp. 152–156, 1997.
[11] H. Meyer, A. Bolarinwa, G. Wolfram, and J. Linseisen, “Bioavailability of apigenin from apiin-rich parsley in humans,” Annals of Nutrition and Metabolism, vol. 50, no. 3, pp. 167–172, 2006.
[12] I. Erlund, E. Meririnne, G. Althan, and A. Aro, “Human nutrition and metabolism: plasma kinetics and urinary excretion of the flavanones naringenin and hesperetin in humans after ingestion of orange juice and grapefruit juice,” Journal of Nutrition, vol. 131, no. 2, pp. 235–241, 2001.
[13] H. Matsumoto, H. Inaba, M. Kishi, S. Tominaga, M. Hirayama, and T. Tsuda, “Orally administered delphinidin 3-rutinoside and cyanidin 3-rutinoside are directly absorbed in rats and humans and appear in the blood as the intact forms,” Journal of Agricultural and Food Chemistry, vol. 49, no. 3, pp. 1546–1551, 2001.
[14] X. Xu, H. J. Wang, P. A. Murphy, L. Cook, and S. Hendrich, “Daidzein is a more bioavailable soymilk isoflavone than is...
genistein in adult women,” *Journal of Nutrition*, vol. 124, no. 6, pp. 825–832, 1994.

[15] Q. Shen, X. Li, D. Yuan, and W. Jia, “Enhanced oral bioavailability of daidzein by self-microemulsifying drug delivery system,” *Chemical and Pharmaceutical Bulletin*, vol. 58, no. 5, pp. 639–643, 2010.

[16] H. Chen, C. Khemtong, X. Yang, X. Chang, and J. Gao, “Nanization strategies for poorly water-soluble drugs,” *Drug Discovery Today*, vol. 16, no. 7–8, pp. 354–360, 2011.

[17] R. T. Bonnecaze and D. R. Lloyd, *Nanoparticle engineering processes: evaporative precipitation into aqueous solution (EPAS) and antisolvent precipitation to enhance the dissolution rates of poorly water soluble drugs [Ph.D. thesis]*, University of Texas, Austin, Tex, USA, 2004.

[18] J. E. Kipp, “The role of solid nanoparticle technology in the parenteral delivery of poorly water-soluble drugs,” *International Journal of Pharmaceutics*, vol. 284, no. 1-2, pp. 109–122, 2004.

[19] S. K. Das, S. Roy, Y. Kalimuthu, J. Khanam, and A. Nanda, “Solid dispersions: an approach to enhance the bioavailability of poorly water-soluble drugs,” *International Journal of Pharmaceutics and Pharmaceutical Technology*, vol. 1, no. 1, pp. 37–46, 2012.

[20] A. T. M. Serajuddin, “Solid dispersion of poorly water-soluble drugs: early promises, subsequent problems, and recent breakthroughs,” *Journal of Pharmaceutical Sciences*, vol. 453, no. 1, pp. 126–141, 2013.

[21] P. Balakrishnan, B. J. Lee, D. H. Oh et al., “Enhanced oral bioavailability of daidzein prodrug by a novel solid Self-emulsifying drug delivery system (SEDDS),” *European Journal of Pharmaceutics and Biopharmaceutics*, vol. 72, no. 3, pp. 539–545, 2009.

[22] R. N. Gursoy and S. Benita, “Self-emulsifying drug delivery systems (SEDDS) for improved oral delivery of lipophilic drugs,” *Biomedicine and Pharmacotherapy*, vol. 58, no. 3, pp. 173–182, 2004.

[23] M. N. Clifford, “Chlorogenic acids and other cinnamates—nature, occurrence and dietary burden,” *Journal of the Science of Food and Agriculture*, vol. 79, no. 3, pp. 362–372, 1999.

[24] F. Sosulski, K. Krygier, and L. Hogge, “Free, esterified, and insoluble-bound phenolic acids. 3: composition of phenolic acids in cereal and potato flours,” *Journal of Agricultural and Food Chemistry*, vol. 30, no. 2, pp. 337–340, 1982.

[25] I. Lempereur, X. Rouau, and J. Abecassis, “Genetic and agroecological variation in arabinoxylan and ferulic acid contents of durum wheat (*Triticum durum* L.) grain and its milling fractions,” *Journal of Cereal Science*, vol. 25, no. 2, pp. 103–110, 1997.

[26] M. Naczk and F. Shahidi, “Extraction and analysis of phenolics in food,” *Journal of Chromatography A*, vol. 1054, no. 1-2, pp. 95–111, 2004.

[27] L. H. Yao, Y. M. Jiang, J. Shi et al., “Flavonoids in food and their health benefits,” *Plant Foods for Human Nutrition*, vol. 59, no. 3, pp. 113–122, 2004.

[28] S. H. Hakkinen, S. O. Kärenlampi, H. M. Mykkänen, I. M. Heinonen, and A. R. Törrönen, “Ellagic acid content in berries: influence of domestic processing and storage,” *European Food Research and Technology*, vol. 212, no. 1, pp. 75–80, 2000.

[29] N. Wang, Z. Y. Wang, S. L. Mo et al., “Ellagic acid, a phenolic compound, exerts anti-angiogenesis effects via VEGFR-2 signaling pathway in breast cancer,” *Breast Cancer Research and Treatment*, pp. 134943–3955, 2012.

[30] C. Bell and S. Hawthorne, “Ellagic acid, pomegranate and prostate cancer—a mini review,” *Journal of Pharmacy and Pharmacology*, vol. 60, no. 2, pp. 139–144, 2008.

[31] M. Boukharta, G. Jalbert, and A. Castonguay, “Biodistribution of ellagic acid and dose-related inhibition of lung tumorigenesis in A/J mice,” *Nutrition and Cancer*, vol. 18, no. 2, pp. 181–189, 1992.

[32] A. González-Sarrias, J. C. Espin, F. A. Tomás-Barberán, and M. T. García-Conesa, “Gene expression, cell cycle arrest and MAPK signalling regulation in Caco-2 cells exposed to ellagic acid and its metabolites, urolithins,” *Molecular Nutrition & Food Research*, vol. 53, no. 6, pp. 686–698, 2009.

[33] M. Larrosa, M. T. García-Conesa, J. C. Espin, and F. A. Tomás-Barberán, “Ellagitannins, ellagic acid and vascular health,” *Molecular Aspects of Medicine*, vol. 31, no. 6, pp. 513–539, 2010.

[34] Y. Porat, A. Abramowitz, and E. Gazit, “Inhibition of amyloid fibril formation by polyphenols: structural similarity and aromatic interactions as a common inhibition mechanism,” *Chemical Biology and Drug Design*, vol. 67, no. 1, pp. 27–37, 2006.

[35] I. Bala, V. Bhardwaj, S. Hariharan, and M. N. V. R. Kumar, “Analytical methods for assay of ellagic acid and its solubility studies,” *Journal of Pharmaceutical and Biomedical Analysis*, vol. 40, no. 1, pp. 206–210, 2006.

[36] B. Li, K. Harich, L. Wiegel, L. S. Taylor, and K. J. Edgar, “Stability and solubility enhancement of ellagic acid in cellulose ester solid dispersions,” *Carbohydrate Polymers*, vol. 92, no. 2, pp. 1443–1450, 2012.

[37] A. Häsiss, W. X. Linag, H. Schwabl, and K. Stampfli, “Flavonoids and tannins: plant-based antioxidants with vitamin character,” *Medical Hypotheses*, vol. 52, no. 5, pp. 479–481, 1999.

[38] J. F. Hammerstone, S. A. Lazarus, and H. H. Schmitz, “Procyanidin content and variation in some commonly consumed foods,” *Journal of Nutrition*, vol. 130, no. 8, pp. 2086S–2092S, 2000.

[39] J. Macheix, A. Fleuriet, and J. Billot, *Flour Phenolics*, CRC Press, Boca Raton, Fla, USA, 1990.

[40] S. F. Price, P. J. Breen, M. Valladao, and B. T. Watson, “Cluster sun exposure and quercetin in Pinot noir grapes and wine,” *The American Journal of Enology and Viticulture*, vol. 46, no. 2, pp. 187–194, 1995.

[41] J. V. Formica, “Review of the biology of quercetin and related bioflavonoids,” *Food and Chemical Toxicology*, vol. 33, no. 12, pp. 1061–1080, 1995.

[42] A. T. Jan, M. R. Kaml, I. Murtaza, J. B. Singh, A. Ali, and Q. M. R. Haq, “Dietary flavonoid quercetin and associated health benefits—an overview,” *Food Reviews International*, vol. 26, no. 3, pp. 302–317, 2010.

[43] P. G. Cadena, M. A. Pereira, R. Cordeiro et al., “Nanoencapsulation of quercetin and resveratrol into elastic liposomes,” *Biochimica et Biophysica Acta*, vol. 1828, no. 2, pp. 309–316, 2012.

[44] L. Gao, G. Liu, X. Wang, F. Liu, Y. Xu, and J. Ma, “Preparation of a chemically stable quercetin formulation using nanosuspension technology,” *International Journal of Pharmaceutics*, vol. 404, no. 1-2, pp. 231–237, 2011.

[45] B. C. Hancock, G. T. Carlson, D. D. Lapidio, B. A. Langdon, and M. P. Mullarney, “Comparison of the mechanical properties of the crystalline and amorphous forms of a drug substance,” *International Journal of Pharmaceutics*, vol. 241, no. 1, pp. 73–85, 2002.
M. S. Anthony, T. B. Clarkson, and J. K. Williams, “Effects of soy isoflavones on atherosclerosis: potential mechanisms,” The American Journal of Clinical Nutrition, vol. 68, no. 6, pp. 1390S–1393S, 1998.

T. Uesugi, Y. Fukui, and Y. Yamori, “Beneficial effects of soybean isoflavone supplementation on bone metabolism and serum lipids in postmenopausal Japanese women: a four-week study,” Journal of the American College of Nutrition, vol. 21, no. 2, pp. 97–102, 2002.

H. K. Suk, Y. K. Sun, W. H. Kyoung et al., “Pharmaceutical evaluation of genistein-loaded pluronic micelles for oral delivery,” Archives of Pharmacal Research, vol. 30, no. 9, pp. 1138–1143, 2007.

X. Vitrac, J. P. Monti, J. Vercauter, G. Deffieux, and J. M. Mérillon, “Direct liquid chromatographic analysis of resveratrol derivatives and flavanonols in wines with absorbance and fluorescence detection,” Analytica Chimica Acta, vol. 458, no. 1, pp. 103–110, 2002.

K. M. Kasiotis, H. Pratisinis, D. Kletas, and S. A. Haroutounian, “Resveratrol and related stilbenes: their anti-aging and anti-angiogenic properties,” Food and Chemical Toxicology, vol. 61, pp. 112–120, 2013.

B. Catalgol, S. Batirel, Y. Taga, and N. K. Ozer, “Resveratrol: French paradox revisited,” Frontiers in Pharmacology, vol. 3, article 141, 2012.

C. C. Udenigwe, V. R. Ramprath, R. F. Aluko, and P. J. H. Jones, “Potential of resveratrol in anticancer and anti-inflammatory therapy,” Nutrition Reviews, vol. 66, no. 8, pp. 445–454, 2008.

A. Duvuri, The formulation of naturally-occurring polyphenolic nutraceutical agents using hot-melt extrusion [M.S. thesis], University of Rhode Island, Kingston, RI, USA, 2011.

X. P. Zhang, Y. Le, J. X. Wang, H. Zhao, and J. F. Chen, “Resveratrol nanodispersion with high stability and dissolution rate,” LWT-Food Science and Technology, vol. 50, no. 2, pp. 622–628, 2012.

M. L. Kuo, T. S. Huang, and J. K. Lin, “Curcumin, an antioxidant and anti-tumor promoter, induces apoptosis in human leukemia cells,” Biochimica et Biophysica Acta, vol. 1317, no. 2, pp. 95–100, 1996.

A. Mazumder, K. Raghavan, J. Weinstein, K. W. Kohn, and Y. Pommier, “Inhibition of human immunodeficiency virus type-1 integrase by curcumin,” Biochemical Pharmacology, vol. 49, no. 8, pp. 1165–1170, 1995.

V. P. Menon and A. R. Sudheer, “Antioxidant and anti-inflammatory properties of curcumin,” Advances in Experimental Medicine and Biology, vol. 595, pp. 105–125, 2007.

H. H. Tønnesen, M. Måsson, and T. Loftsson, “Studies of curcumin and curcuminoids. XXVII: cyclodextrin complexation: solubility, chemical and photochemical stability,” International Journal of Pharmaceutics, vol. 244, no. 1-2, pp. 127–135, 2002.

R. A. Sharma, S. A. Euden, S. L. Platon et al., “Phase I clinical trial of oral curcumin: biomarkers of systemic activity and compliance,” Clinical Cancer Research, vol. 10, no. 20, pp. 6847–6854, 2004.

M. Kakran, N. G. Sahoo, I. L. Tan, and L. Li, “Preparation of nanoparticles of poorly water-soluble antioxidant curcumin by antisolvent precipitation methods,” Journal of Nanoparticle Research, vol. 14, no. 3, article 757, 2012.

M. Mosharraf and C. Nyström, “The effect of particle size and shape on the surface specific dissolution rate of microsized practically insoluble drugs,” International Journal of Pharmaceutics, vol. 122, no. 1-2, pp. 35–47, 1995.

S. Onoue, H. Takahashi, Y. Kawabata et al., “Formulation design and photochemical studies on nanocrystal solid dispersion of curcumin with improved oral bioavailability,” Journal of Pharmaceutical Sciences, vol. 99, no. 4, pp. 1871–1881, 2010.

P. Zhang, Y. Liu, N. Feng, and J. Xu, “Preparation and evaluation of self-microemulsifying drug delivery system of oridonin,” International Journal of Pharmaceutics, vol. 355, no. 1-2, pp. 269–276, 2008.

J. Cui, B. Yu, Y. Zhao et al., “Enhancement of oral absorption of curcumin by self-microemulsifying drug delivery systems,” International Journal of Pharmaceutics, vol. 371, no. 1-2, pp. 148–155, 2009.